Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

The Department of Health purchased the largest remaining independent US plasma collector, Life Resources Incorporated, to ensure the continuity of supply without needing to rely on UK-sourced plasma.

Published on: 22 July, 2024

The death of a patient thought to have been infected with vCJD through transfusion was announced. 15 individuals who received donations of blood from donors who subsequently developed vCJD were to be notified by the Health Protection Agency.

Published on: 22 July, 2024

The Government announced the exclusion of blood donors who had received transfusions of whole blood components since January 1980.

Published on: 22 July, 2024

The second case of transfusion-related vCJD was reported.

Published on: 22 July, 2024

People with a bleeding disorder who were treated with UK-sourced pooled factor concentrates or antithrombin between 1980 and 2001 were considered at risk of vCJD and informed by their haemophilia centre.

Published on: 22 July, 2024

WHO identified record keeping as key to reducing the risks of hepatitis.

Published on: 22 July, 2024

Guidance and circulars were issued containing advice as to the retention and disposal of medical records.

Published on: 22 July, 2024

The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody was opposed to the "routine determination of transaminase levels" but considered further investigation to be warranted and deferred further discussions to its next meeting when Dr Cleghorn would be in attendance.

Published on: 24 July, 2024

The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody's terms of reference included "To advise the Department on measures which should be introduced to offer greater safety to recipients of blood and blood products and to protect the interests of blood donors."

Published on: 24 July, 2024

Dr Cleghorn reported that several people had "raised transaminases not associated with viral hepatitis. Some 3% of new donors would be excluded if the criterion of one raised transaminase was applied. In addition there would be a problem of responsibility to apparently healthy donors found to have raised transaminase(s)."

Published on: 24 July, 2024

"The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody agreed that no new policy on testing for transaminases needed to be adopted. These tests should not be used to screen blood donors."

Published on: 24 July, 2024

The Blood Transfusion Research Committee concluded that "The identification of donors and units of blood associated with possible cases of non-A, non-B hepatitis" and "Epidemiological surveys to assess the size of the problem in relation to blood transfusions" required investigation.

Published on: 24 July, 2024

Dr Paul Holland acknowledged that ALT screening of donors appeared to be a "promising way to decrease the risk of post-transfusion hepatitis", and questioned whether the expected benefit to patients was "worth the drawbacks, especially to the donors and to the blood-service complex".

Published on: 24 July, 2024

Dr Brian McClelland reported to the SNBTS directors that he had prepared a protocol for a study of the transmission of NANBH by transfusion for an MRC meeting. Directors agreed at the meeting that they would not proceed with liver function tests on existing donations for the time being.

Published on: 24 July, 2024

Report on Post-transfusion hepatitis in a London hospital: results of a two-year prospective study was published. The report explained that "It was arbitrarily decided that where such other potential causes existed, the patient would not be regarded as suffering from viral hepatitis." It also acknowledged that the "exclusion of all patients having other possible causes for their liver damage may have contributed to the low incidence of hepatitis in the present study".

Published on: 24 July, 2024

The MRC Blood Transfusion Committee was disbanded in July 1982 on the basis that its work was being duplicated elsewhere.

Published on: 24 July, 2024

The Advisory Group on Testing for the Presence of Hepatitis B Surface Antigen and Its Antibody advised against screening tests for NANBH in screening blood donors.

Published on: 24 July, 2024

The DHSS Advisory Group on Hepatitis endorsed the Third Report of the Advisory Group on Testing for the Presence of Hepatitis B Surface Antigen and Its Antibody, advising against NANBH screening.

Published on: 24 July, 2024

The merits and drawbacks of NANBH surrogate screening were discussed in an editorial in The Lancet.

Published on: 24 July, 2024

At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Brian McClelland would produce an outline study protocol, which might include non-specific markers like ALT level and/or the presence of anti-HBc in donors.

Published on: 24 July, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2013
  • Page 2014
  • Page 2015
  • Page 2016
  • Current page 2017
  • Page 2018
  • Page 2019
  • Page 2020
  • Page 2021
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.